leisure time -WSS

leisure time

author：hotspot 2025-09-30 00:50:43 - browse：6

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Ford recalls 870K F

hotspot

focus

WSS

Astellas still sees hope in its gene therapy after four deaths

PBM reforms clear House panel

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Ending health disparities requires full federal government, panel says

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Ford recalls 870K F

leisure time

leisure time

explore

Sports medicine is finally prioritizing gender equality

Poor hospice wound care hurts patients and families

Malaria cases in Florida and Texas: Here’s what you need to know

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Activists slam private health insurers over coverage restrictions

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Trump demands the U.S. pay no more for drugs than other countries … again

Behind warning on Apellis’s eye drug lies a conflict of interest

Duchenne breakthrough therapy leaves behind pioneering families

Morphosys mixed study results for blood cancer drug

leisure time

VC firm RA Capital starts a new synthetic biology incubator

Poor hospice wound care hurts patients and families

The mammogram wars are not over

Congress must reauthorize a committee to support older Americans

In key trial, Verve's treatment lowers cholesterol levels in patients

Weight loss drug costs may need more research, senator suggests

hotspot

focus

hotspot

explore